To the full analysis
Jiangsu Hengrui Pharmaceuticals stock: growth
1276.HKJiangsu Hengrui Pharmaceuticals reported $4.47B in revenue for fiscal 2025, up 18.2% on the prior year, up 2.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
18.5%
per year from 2006 to 2025, per share 18.3%
Earnings (Annual rate)
21.8%
per year from 2006 to 2025, per share 23.3%
Free cash flow (Annual rate)
23.2%
per year from 2006 to 2025, per share 22.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.6% | 12.0% | 18.5% |
| Revenue per share | 2.2% | 11.7% | 18.3% |
| Earnings | 3.8% | 12.3% | 21.8% |
| Earnings per share | 3.3% | 11.9% | 23.3% |
| Free cash flow | 20.5% | 14.8% | 23.2% |
| Free cash flow per share | 20.1% | 14.4% | 22.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $177.69M | $25.6M | $22.25M |
| 2007 | $257.88M | $54M | $18.66M |
| 2008 | $340.32M | $60.16M | $888.72K |
| 2009 | $436.28M | $95.89M | $43.53M |
| 2010 | $545.54M | $105.52M | $14.59M |
| 2011 | $685.08M | $134M | −$1.91M |
| 2012 | $833.29M | $168.12M | $76.73M |
| 2013 | $976.43M | $198.29M | $146.03M |
| 2014 | $1.17B | $242.11M | $203.83M |
| 2015 | $1.43B | $340M | $294.89M |
| 2016 | $1.62B | $383.97M | $220.28M |
| 2017 | $1.99B | $470.8M | $324.48M |
| 2018 | $2.59B | $611.25M | $374.82M |
| 2019 | $3.33B | $766.87M | $512.81M |
| 2020 | $3.92B | $902.64M | $459.14M |
| 2021 | $3.94B | $693.04M | $430.48M |
| 2022 | $3.08B | $564.73M | −$105.09M |
| 2023 | $3.21B | $604.45M | $865.4M |
| 2024 | $3.78B | $855.63M | $736.4M |
| 2025 | $4.47B | $1.09B | $1.17B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.